The United Kingdom and the United States have concluded a landmark commercial pact that will ensure zero levies on British medicine products going into the American market.
The Terms of the Accord
Under the terms of the agreement, the UK has agreed to increase spending on drugs through the NHS. This commitment secures that duties on these crucial products will remain at zero for a timeframe of three years.
This agreement comes after recent statements to dramatically increase import taxes on patented drug imports, with increases discussed reaching double the cost.
"This deal with the Britain reinforces the global environment for cutting-edge drugs and establishes long-overdue equity to U.S.–U.K. medicine commerce," an announcement noted.
Trade Significance
Pharmaceuticals are one of the Britain's biggest exports to the United States, which is clearly the biggest destination for leading British pharmaceutical firms.
Trade data indicate that in the year leading up to September, the UK exported medicines worth £11.1bn to the US. This amount represented nearly one-fifth of total UK exports in that timeframe.
"This guarantee safeguards work, boosts funding and sets the stage for the UK to emerge as a global hub for medical research," the Business and Trade Secretary stated.
Detailed British Pledges
The deal entails several specific commitments from the United Kingdom:
- Price Threshold Increase: The UK will raise the affordability limit at which it judges new medicines to be prohibitively costly by 25%.
- Increased NHS Spending: There is a target to double overall health service expenditure on treatments from 0.3 percent of the national economy to 0.6% over the next decade.
- Refund Ceiling: The sum pharmaceutical firms must refund to the NHS to control costs will be limited at 15%. Last year, refunds were more than 20%.
Industry Background
The deal takes place against a ongoing tension between the pharmaceutical industry and the UK government over medicine costs and approval rates.
These tensions were heightened by assertions that US patients were charged several times more for the identical medicines than patients in the UK and Europe.
In recent months, several major pharmaceutical investments in the UK have been paused or scrapped, while substantial investments have been pledged toward US facilities.
One official acknowledged that the NHS needed to spend more on drugs, noting that its budget allocation on drugs had shrunk as a proportion of its resources over the past decade.
